Research shows that cost-plus pricing can lower drug costs dramatically, depending on where in the supply chain the markup is applied.
|Articles|January 10, 2005
Entecavir shows promise for chronic hepatitis B
Hepatitis B virus (HBV) is a major healthcare problem around the world. It is estimated that 350 million to 400 million people are chronically infected. The development and approval of oral antihepatitis B virus agents, lamivudine, and, more recently, adefovir dipivoxil, revolutionized the treatment of chronic hepatitis B. However, the emergence of resistant HBV mutants remains the main factor limiting the efficacy of antiviral therapy.With lamivudine, the problem of resistance is very frequent and progressively increases with prolongation of therapy (> 50% at three years).
Advertisement
Advertisement
Related to this article
Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.
In part 1 of our midterm election FAQ series, AJ Barbarito, Esq, breaks down ongoing legal developments for pharmacists and what a change in Congressional control could mean for the profession.
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
As a government price-setting formula, the same arithmetic has produced the opposite result.
Orforglipron lowered A1C and body weight more than oral semaglutide 25 mg at 52 weeks, but the estimate comes from an indirect comparison.
Brian Smith, PharmD, explains how direct-to-consumer GLP-1 pathways broaden initial access but endanger long-term patient adherence.
Pharmacists face burnout and financial strain as PBMs take big cuts, prompting urgent calls for reform to protect patient care and community pharmacies.
Advertisement
Advertisement